Our resource hub is home to a wealth of articles, stories and videos about managing and living with type 1 diabetes.
Place your order for our free information packs that support adults and children who have been recently diagnosed.
Our researchers are working on different ways to develop a cure for type 1 diabetes - from growing insulin-producing beta cells in labs to hacking the immune system.
Learn about the technologies that can deliver insulin automatically when needed. And discover the next generation of insulins that are currently being developed.
Find the perfect cards to make your season’s greetings go even further. Every pack purchased will help fund vital research and support for people living with type 1 diabetes.
Researchers need your help. By taking part in research studies and clinical trials, you will help them make progress to improve lives and find a cure for type 1 diabetes.
Our ambitious new roadmap is aimed at driving significant advancements in type 1 diabetes research, treatment, and care.
Your donation helps support people living with type 1 diabetes and funds the best treatment and cure research.
We provide a wealth of information and free resources to help you support and empower your patients or students.
Take our free course for schools to learn more about supporting pupils with type 1 diabetes in educational settings.
Home > News & events > News > Professor Colin Dayan presented with the 2023 JDRF Rumbough Award
The JDRF David Rumbough Award acknowledges an individual who has made outstanding contributions in the field of type 1 diabetes that have significantly accelerated our mission.
For over 20 years, Professor Dayan has been a leader in type 1 immunotherapy research, and his work has been central to our research strategy and overall mission. He has led the efforts to bring teplizumab to the UK.
He is a leading member of the Breakthrough T1D-funded UK Type 1 Diabetes Research Consortium, through which he has brought the research community together to accelerate critical research, leverage collective resources, and collaborate to improve type 1 clinical trial delivery.
Currently, Professor Dayan serves as Professor of Clinical Diabetes and Metabolism at Cardiff University and as part-time senior clinical researcher in the Nuffield Department of Medicine at the University of Oxford.
Breakthrough T1D Chief Scientific Officer Sanjoy Dutta, Ph.D says: “Professor Dayan has played a significant role in advancing disease-modifying therapies for type 1 diabetes that will continue to have a profound impact on the global type 1 research community and those who are affected by the condition. JDRF is proud to honour Professor Dayan for his indelible contributions and work that supports and furthers our mission.”
Donate to JDRF today so that we can continue funding amazing research to develop cures and treatments for type 1 diabetes.
A US clinical trial is exploring whether tegoprubart could make islet transplants an option for people with type 1 diabetes (T1D) and kidney disease, with funding from Breakthrough T1D.
The inaugural Breakthrough T1D Clinical & Research Congress (CRC) brought together more than 1,000 clinicians, researchers, industry leaders and members of the type 1 diabetes (T1D) community from around the world.
The European Association for the Study of Diabetes (EASD) is the continent's largest diabetes conference. It brought together researchers from around the world to share the latest developments in type 1 diabetes (T1D) research.
New Breakthrough T1D-funded research from Harvard, USA, has found a link between how gut bacteria develops in early childhood and the risk of type 1 diabetes (T1D).
Would you like to visit the website of our {{ affiliate_country }} affiliate to complete your action?
